000202035 001__ 202035
000202035 005__ 20210129220010.0
000202035 0247_ $$2doi$$a10.1016/j.neuropharm.2012.06.040
000202035 0247_ $$2ISSN$$a0028-3908
000202035 0247_ $$2ISSN$$a1873-7064
000202035 0247_ $$2WOS$$aWOS:000311250300023
000202035 0247_ $$2altmetric$$aaltmetric:2096452
000202035 0247_ $$2pmid$$apmid:22766391
000202035 037__ $$aFZJ-2015-04324
000202035 082__ $$a610
000202035 1001_ $$0P:(DE-HGF)0$$aWinterer, Georg$$b0$$eCorresponding Author
000202035 245__ $$aAllosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study
000202035 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2013
000202035 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1435666446_1776
000202035 3367_ $$2DataCite$$aOutput Types/Journal article
000202035 3367_ $$00$$2EndNote$$aJournal Article
000202035 3367_ $$2BibTeX$$aARTICLE
000202035 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000202035 3367_ $$2DRIVER$$aarticle
000202035 520__ $$aIn this multicenter, double-blind, placebo-controlled, randomized, four way cross-over proof-of-mechanism study, we tested the effect of the positive allosteric α7 nicotinic acetylcholine receptor (nAChR) modulator JNJ-39393406 in a key translational assay (sensory P50 gating) in 39 regularly smoking male patients with schizophrenia. All patients were clinically stable and JNJ-39393406 was administered as an adjunct treatment to antipsychotics. No indication was found that JNJ-39393406 has the potential to reverse basic deficits of information processing in schizophrenia (sensory P50 gating) or has a significant effect on other tested electrophysiological markers (MMN, P300 and quantitative resting EEG). Sensitivity analyses including severity of disease, baseline P50 gating, medication and gene variants of the CHRNA7 gene did not reveal any subgroups with consistent significant effects. It is discussed that potential positive effects in subgroups not present or not large enough in the current study or upon chronic dosing are possible, but unlikely to be developed.
000202035 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000202035 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de
000202035 7001_ $$0P:(DE-HGF)0$$aGallinat, Jürgen$$b1
000202035 7001_ $$0P:(DE-HGF)0$$aBrinkmeyer, Jürgen$$b2
000202035 7001_ $$0P:(DE-HGF)0$$aMusso, Francesco$$b3
000202035 7001_ $$0P:(DE-HGF)0$$aKornhuber, Johannes$$b4
000202035 7001_ $$0P:(DE-HGF)0$$aThuerauf, Norbert$$b5
000202035 7001_ $$0P:(DE-HGF)0$$aRujescu, Dan$$b6
000202035 7001_ $$0P:(DE-HGF)0$$aFavis, Reyna$$b7
000202035 7001_ $$0P:(DE-HGF)0$$aSun, Yu$$b8
000202035 7001_ $$0P:(DE-HGF)0$$aFranc, Monique A.$$b9
000202035 7001_ $$0P:(DE-HGF)0$$aOuwerkerk-Mahadevan, Sivi$$b10
000202035 7001_ $$0P:(DE-HGF)0$$aJanssens, Luc$$b11
000202035 7001_ $$0P:(DE-HGF)0$$aTimmers, Maarten$$b12
000202035 7001_ $$0P:(DE-HGF)0$$aStreffer, Johannes R.$$b13
000202035 773__ $$0PERI:(DE-600)1500655-4$$a10.1016/j.neuropharm.2012.06.040$$gVol. 64, p. 197 - 204$$p197 - 204$$tNeuropharmacology$$v64$$x0028-3908$$y2013
000202035 8564_ $$uhttps://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.pdf$$yRestricted
000202035 8564_ $$uhttps://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.gif?subformat=icon$$xicon$$yRestricted
000202035 8564_ $$uhttps://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000202035 8564_ $$uhttps://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.jpg?subformat=icon-180$$xicon-180$$yRestricted
000202035 8564_ $$uhttps://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.jpg?subformat=icon-640$$xicon-640$$yRestricted
000202035 8564_ $$uhttps://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.pdf?subformat=pdfa$$xpdfa$$yRestricted
000202035 909CO $$ooai:juser.fz-juelich.de:202035$$pVDB
000202035 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000202035 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000202035 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000202035 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000202035 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000202035 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000202035 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000202035 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000202035 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000202035 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000202035 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000202035 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000202035 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000202035 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000202035 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF <  5
000202035 920__ $$lyes
000202035 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000202035 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000202035 980__ $$ajournal
000202035 980__ $$aVDB
000202035 980__ $$aI:(DE-Juel1)INM-3-20090406
000202035 980__ $$aI:(DE-Juel1)INM-4-20090406
000202035 980__ $$aUNRESTRICTED
000202035 981__ $$aI:(DE-Juel1)INM-4-20090406